Endoluten®
and chemotherapy as an adjunct to conventional complex treatment. Before treatment, all
patients showed a change in the blood count, which was expressed primarily in leukopenia and
lymphocytopenia. Patients complained of poor health, decreased muscle tone, reduced appetite,
and apathy.
Influence of Endoluten®on immunological blood parameters of cancer Table 4
patients.
Indicator Norm БPatients
Before After Treatment with After Treatment with
Treatment Conventional Means Endoluten® (Primary
(Control Group) Group)
Leukocytes, x109/l 4,0-8,8 3,14±0,11* 4,14±0,21 4,87±0,32#
Lymphocytes, x109/l 1,96±0,06 0,89±0,14* 1,42±0,18# 1,78±0,13#^
T-lymphocytes,x109/l 1,05±0,05 0,39±0,02* 0,61±0,05*# 0,79±0,04#^
"Active" T-lymphocytes (A-ROCK),x109/l 0,59±0,04 0,29±0,07* 0,35±0,06* 0,39±0,01*
RTML with KonA,% 59,1±1,7 91,5±3,8* 74,7±4,3*# 64,6±4,3#^
B-lymphocytes (EAC-ROCK), x109/l 0,53±0,04 0,30±0,06* 0,34±0,07 0,37±0,02
* p <0.05 - statistically significant compared with the normal indicator;
# p <0.05 - statistically significant compared with the indicator before treatment;
^p <0.05 - statistically significant compared with the indicator in the control group.
When ENDOLUTEN® was used in cancer patients of the primary group, a significant increase in the
total number of leukocytes, lymphocytes, and T-lymphocytes in the blood was noted, as well as an
improvement in the functional activity of T-cells (Table 4). These changes correlated with the positive
dynamics of the subjective state, expressed in improved appetite, sleep, increased muscle tone, and
decreased feelings of apathy.
As a result of the study, it was shown that ENDOLUTEN® is advisable to use in cancer patients after
courses of radiation and chemotherapy to improve the general condition, maintain hematological and
immunological parameters in the peripheral blood at the optimal level, and prevent the development
of infectious complications.
When ENDOLUTEN® was included in the complex treatment regimens for various diseases associated
with impaired neuroendocrine regulation, no side effects, complications, or drug dependence were
identified.
Thus, the results obtained indicate the therapeutic and prophylactic efficacy of ENDOLUTEN® and the
practicality of its use for prevention and in the complex treatment of various pathological conditions
and diseases associated with impaired neuroendocrine regulation of the main functions of the body.
CONCLUSION
The biologically active food supplement ENDOLUTEN® has a normalizing effect on metabolism in
the neuroendocrine system cells, particularly the pineal gland (pineal gland), and helps restore the
neuroendocrine regulation of the body’s main functions.
ENDOLUTEN® is well tolerated when taken orally, has no side effects, and can be widely used as a
therapeutic and prophylactic biologically active food supplement.
ENDOLUTEN® is recommended for use:
- To patients with dyshormonal myocardial dystrophy - orally 10-15 minutes before meals, 1-3 capsules
2-3 times a day for 15-30 days, depending on the severity of the pathological process;
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.